WO2020160619A1 - Composition de réduction de glycation et procédé d'utilisation correspondant - Google Patents

Composition de réduction de glycation et procédé d'utilisation correspondant Download PDF

Info

Publication number
WO2020160619A1
WO2020160619A1 PCT/AU2020/050094 AU2020050094W WO2020160619A1 WO 2020160619 A1 WO2020160619 A1 WO 2020160619A1 AU 2020050094 W AU2020050094 W AU 2020050094W WO 2020160619 A1 WO2020160619 A1 WO 2020160619A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
vitamin
formulated
amount
present
Prior art date
Application number
PCT/AU2020/050094
Other languages
English (en)
Inventor
Raymond Denis PALMER
Original Assignee
Helium 3 Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019900346A external-priority patent/AU2019900346A0/en
Application filed by Helium 3 Biotech Pty Ltd filed Critical Helium 3 Biotech Pty Ltd
Publication of WO2020160619A1 publication Critical patent/WO2020160619A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present disclosure relates to a glycation reducing composition and a method of use thereof.
  • advanced glycation endproducts include reactive products that lead to cell damage, which is thought to be associated with age-related dysfunction of tissues and/or organs. Additionally, advanced glycation endproducts are also potentially associated with the development of morbidities within the ageing populations world-wide.
  • compositions that will reduce the concentration of advanced glycation endproducts in a cell when administered in a therapeutically effective dose to a subject in need thereof and a method of using such a composition.
  • Advanced glycation endproducts accumulate in multicellular organisms, such as humans, with the passage of time. Accumulation of advanced glycation endproducts is associated with deleterious effects that are typically termed“ageing”. These deleterious effects, including a deterioration of cell function, lead to an increase of ageing-related pathologies and inevitably accelerate mortality. A reduction in the concentration of advanced glycation endproducts may delay onset of ageing-related negative effects on the health of an individual and contribute to economic benefits insofar as the costs associated with an increase in the ageing populations world-wide may be diminished.
  • the present disclosure in one aspect sets forth a composition including a therapeutically effective dose of each of b-alanine, aminoguanidine, carcinine, carnosine, pyridoxamine, quercetin, and vitamin E, the composition formulated to reduce the concentration of an advanced glycation endproduct in a cell of a subject.
  • the present disclosure in another aspect sets forth a method of reducing the concentration of an advanced glycation endproduct in a cell of a subject, the method including administering to a subject in need thereof a therapeutically effective dose of each of b-alanine, aminoguanidine, carcinine, carnosine, pyridoxamine, quercetin, and vitamin E.
  • the present disclosure is directed to a composition that reduces the concentration of advanced glycation endproducts in one or more cell of a multicellular organism, such as humans, that may arise with the passage of time.
  • the present disclosure also relates to a method of use of the composition.
  • the term“advanced glycation endproducts” should be understood for the purposes herein to define that those compounds that are formed when a protein or a lipid combine with a carbohydrate in one or more cell of an organism.
  • composition formulated to reduce the concentration of an advanced glycation endproduct in a cell of a subject.
  • the composition including a therapeutically effective dose of each of b-alanine, aminoguanidine, carcinine, carnosine, pyridoxamine, quercetin, and vitamin E.
  • a therapeutically effective dose refers to an amount of a composition administered to a subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
  • each of b-alanine, aminoguanidine, carcinine, carnosine, pyridoxamine, quercetin, and vitamin E is present in an amount of 20 - 150 mg.
  • b-alanine is present in an amount of 40 mg.
  • aminoguanidine is present in an amount of 10 mg.
  • carcinine is present in an amount of 50 mg.
  • carnosine is present in an amount of 50 mg.
  • pyridoxamine is present in an amount of 50 mg.
  • quercetin is present in an amount of 50 mg.
  • vitamin E is present in an amount of 40 mg.
  • the vitamin E is a-tocopherol. In another preferred embodiment, the vitamin E is b-tocopherol. In another preferred embodiment, the vitamin E is g-tocopherol. In another preferred embodiment, the vitamin E is d-tocopherol. In another preferred embodiment, the vitamin E is a- tocotrienol. In another preferred embodiment, the vitamin E is b- tocotrienol. In another preferred embodiment, the vitamin E is y- tocotrienol. In another preferred embodiment, the vitamin E is d- tocotrienol.
  • composition herein disclosed may be delivered to a subject in need thereof by any one of several routes.
  • the composition may be delivered via buccal, infusion (e.g., a bolus infusion), inhalation, intracranial injection, enteral, intradermal, intramuscular, intranasal, intraocular, intraperitoneally, intravenously, orally, rectal, rectal, subcutaneously, sublingual, topically, transdermal, vaginal, or any combination thereof.
  • the composition may be formulated for enteral administration.
  • composition herein disclosed may be formulated for delayed release (also termed sustained or slow release, timed release, delayed release, or controlled release).
  • delayed release also termed sustained or slow release, timed release, delayed release, or controlled release.
  • Such compositions may generally be prepared using well known technology and administered by, for example, oral, rectal, intradermal, or subcutaneous implantation, or by implantation at the desired target site in a delayed release manner.
  • Delayed-release formulations may contain the compound dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling barrier.
  • a particularly preferred embodiment of the composition may be formulated in an enteric coating layer.
  • the enteric coating layer may include one or more of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, and water-based polymer solutions or dispersions of acrylates.
  • the composition disclosed herein may be formulated with a buffering agent to protect the compound from low pH of the gastric environment and/or an enteric coating.
  • composition when administer orally, buccally, or sublingually, may be formulated with a flavouring agent, e.g., in a liquid, solid or semi-solid formulation.
  • a flavouring agent e.g., in a liquid, solid or semi-solid formulation.
  • Preferred embodiments may include one or more pharmaceutically acceptable dispersant, excipient, pH-buffering compound, and pigment.
  • Preferred embodiments will include at least one excipient that is biocompatible and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release.
  • the excipient facilitates absorption. In yet a further particularly preferred embodiment, the excipient enhances solubility.
  • the composition may be a tablet formulation.
  • the composition may be a powder formulation.
  • the powder formulation may be in a capsule.
  • the composition may be a liquid formulation.
  • the composition may be formulated for parenteral administration.
  • the composition may be formulated for subcutaneous administration.
  • the composition may be formulated for intramuscular administration.
  • the composition may be formulated for intravenous administration.
  • the composition may be formulated for intradermal administration.
  • the composition may be formulated for transdermal administration.
  • composition disclosed herein will be administered for a sufficient amount of time to selectively purge senescent cells from one or more tissue in a subject, wherein the purging of such cells does not lead to a cancer.
  • purging of senescent cells may ameliorate at least one symptom associated with a number of pathologies.
  • Such pathologies may include age-related loss of pulmonary function, Alzheimer's disease, angina, aortic aneurysm, arrhythmia, arteriosclerosis, asthma, atherosclerosis, atopic dermatitis, brain aneurysm, bronchiectasis, cardiac diastolic dysfunction, a cancer, cardiac fibrosis, cardiac stress resistance, cardiomyopathy, carotid artery disease, cataracts, chronic obstructive pulmonary disease, chronic renal failure, congestive heart failure, coronary artery disease, coronary thrombosis, cutaneous lupus, cutaneous lymphomas, cystic fibrosis, dementia, diabetes, diabetic ulcer, diseases and disorders related to photosensitivity or photoaging, dysesthesia, eczema, eczematous eruptions, emphysema, endocarditis, eosinophilic dermatosis, fibrohistocytic proliferations of skin, frailty, glaucoma,
  • a method of reducing the concentration of an advanced glycation endproduct in a cell of a subject including administering to a subject in need thereof a therapeutically effective dose of each of b-alanine, aminoguanidine, carcinine, carnosine, pyridoxamine, quercetin, and vitamin E.
  • the method may include a treatment course no longer than (a) one month, or (b) no longer than two months, or (c) no longer than three months.
  • each treatment course is no longer than (a) five days, (b) seven days, (c) ten days, (d) fourteen days, or (e) twenty-one days.
  • the composition is administered every second day or every third day of each treatment course.
  • the composition is administered once daily during each treatment course.
  • the composition is administered twice daily during each treatment course. Suitable interval periods between treatments will be known to a person skilled in the art.
  • the subject may be a multicellular animal.
  • the multicellular animal is a human.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention est motivée par le fait qu'un certain nombre de réactions complexes, comprenant des réactions d'Amadori, des réactions de Maillard et des réactions de base de Schiff, conduisent à une augmentation de la concentration en produits terminaux de glycation avancée dans les cellules au fur et à mesure du vieillissement des animaux, y compris les êtres humains. De tels produits terminaux de glycation avancée comprennent des produits réactifs qui conduisent à un dommage cellulaire, dont on pense qu'il est associé à un dysfonctionnement lié à l'âge de tissus et/ou d'organes. De plus, les produits terminaux de glycation avancée sont également potentiellement associés au développement de morbidités dans les populations vieillissantes partout dans le monde. Compte tenu du dysfonctionnement et des morbidités mentionnés ci-dessus dans les populations vieillissantes partout dans le monde, il existe un besoin d'une composition qui réduira la concentration en produits terminaux de glycation avancée dans une cellule lorsqu'elle est administrée dans en dose thérapeutiquement efficace à un sujet qui en a besoin et d'un procédé d'utilisation d'une telle composition. La présente invention concerne une composition de réduction de la glycation et un procédé de préparation associé.
PCT/AU2020/050094 2019-02-05 2020-02-05 Composition de réduction de glycation et procédé d'utilisation correspondant WO2020160619A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019900346A AU2019900346A0 (en) 2019-02-05 A glycation reducing composition and method of use thereof
AU2019900346 2019-02-05

Publications (1)

Publication Number Publication Date
WO2020160619A1 true WO2020160619A1 (fr) 2020-08-13

Family

ID=71948391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2020/050094 WO2020160619A1 (fr) 2019-02-05 2020-02-05 Composition de réduction de glycation et procédé d'utilisation correspondant

Country Status (1)

Country Link
WO (1) WO2020160619A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022039190A1 (fr) * 2020-08-18 2022-02-24 有機合成薬品工業株式会社 Activateur des sirtuines et procédé d'activation des sirtuines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US20060216251A1 (en) * 2005-03-24 2006-09-28 Tracie Martyn International, Llc Topical formulations and methods of use
US20070065396A1 (en) * 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation
EP2939657A1 (fr) * 2012-12-27 2015-11-04 Hayashibara Co., Ltd. Composition antivieillissement pour l'extérieur de la peau et procédé de production associé

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045896A1 (en) * 2004-08-31 2006-03-02 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
US20060216251A1 (en) * 2005-03-24 2006-09-28 Tracie Martyn International, Llc Topical formulations and methods of use
US20070065396A1 (en) * 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation
EP2939657A1 (fr) * 2012-12-27 2015-11-04 Hayashibara Co., Ltd. Composition antivieillissement pour l'extérieur de la peau et procédé de production associé

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022039190A1 (fr) * 2020-08-18 2022-02-24 有機合成薬品工業株式会社 Activateur des sirtuines et procédé d'activation des sirtuines

Similar Documents

Publication Publication Date Title
DK2376077T3 (en) Preparation and method of treating diabetes
US20100029578A1 (en) Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds
KR20150046039A (ko) 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제
Kiuchi et al. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: a case report
JP2019142925A (ja) 糖尿病の治療用組成物および方法
WO2020160617A1 (fr) Composition de modulation de l'expression et de la distribution de protéines membranaires et son procédé d'utilisation
WO2020160619A1 (fr) Composition de réduction de glycation et procédé d'utilisation correspondant
WO2017006254A1 (fr) Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2020160618A1 (fr) Composition anti-sénescence cellulaire et procédé d'utilisation
WO2020160620A1 (fr) Composition d'atténuation de la dérive épigénétique et procédé d'utilisation associé
WO2016132483A1 (fr) Inhibiteur de chymase humaine et médicament pour prévenir et traiter une maladie associée à une activité de chymase humaine
JP5364168B2 (ja) ジペプチジルペプチダーゼ−ｉｖの活性を阻害する化合物及び異なる抗糖尿または抗肥満薬物を有効成分として含む糖尿または肥満の予防及び治療用薬学的組成物
US8455526B2 (en) Therapeutic use of imidazole-5-carboxylic acid derivatives
WO2015025816A1 (fr) Inhibiteur de chymase et médicament contenant de l'inhibiteur de chymase
US20140206674A1 (en) Combinations with 2-aminoethanesulfonic acid
US20220054406A1 (en) Composition and method for treatment of diabetes
US20230133176A1 (en) Composition and method for treatment of diabetes
US20150224081A1 (en) Composition and method for treatment of diabetes
US20230149300A1 (en) Composition and method for treatment of diabetes
JP6364362B2 (ja) ヒトキマーゼ阻害剤および機能性食品、並びにヒトキマーゼの活性を阻害する方法
TWI671070B (zh) 用於製造與人類凝乳酶的活性相關疾病之預防治療用藥劑之具有黃酮醇骨架之化合物或其藥學上容許之鹽的用途
Rossen et al. Oral levodopa in the long-term treatment of heart failure
DE102009053157A1 (de) Arzneimittel enthaltend Cholin
WO2001013911A1 (fr) Agents inhibiteurs des troubles d'hypertension arterielle
JP2006517223A (ja) 抗糖尿病薬の組み合わせ

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE